Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Lexaria Bioscience Corp (LEXX)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: LEXX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -28.62% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 2.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.95M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 237481 | Beta 1.06 | 52 Weeks Range 1.36 - 6.85 | Updated Date 01/14/2025 |
52 Weeks Range 1.36 - 6.85 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-01-10 | When After Market | Estimate -0.12 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) -2074.9% |
Management Effectiveness
Return on Assets (TTM) -38.21% | Return on Equity (TTM) -70.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27964946 | Price to Sales(TTM) 87.47 |
Enterprise Value 27964946 | Price to Sales(TTM) 87.47 | ||
Enterprise Value to Revenue 67.37 | Enterprise Value to EBITDA -7.22 | Shares Outstanding 17452600 | Shares Floating 13225553 |
Shares Outstanding 17452600 | Shares Floating 13225553 | ||
Percent Insiders 7.03 | Percent Institutions 6.08 |
AI Summary
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stock Overview
Company Profile:
History and Background: Lexaria Bioscience Corp. is a Canadian biotechnology company founded in 1994. The company focuses on developing and commercializing innovative drug delivery platforms. Its main platform technology is DehydraTECH, which improves the bioavailability and absorption of various active pharmaceutical ingredients (APIs) by increasing their water solubility.
Core Business Areas: The company's core business areas include:
- Developing and licensing DehydraTECH technology for pharmaceuticals, nutraceuticals, and cosmetics.
- Developing and marketing its own consumer products containing DehydraTECH.
- Providing contract research and development services to other companies.
Leadership and Corporate Structure: Lexaria's leadership team consists of:
- Chris Bunka, PhD: Chief Executive Officer (CEO)
- John Docherty, PhD: Chief Science Officer (CSO)
- Christopher DeFeo: Chief Legal Officer and General Counsel
- John Traub: Chief Financial Officer (CFO)
- Jeffery Yapp: President and Business Development
Top Products and Market Share:
- Lexaria's top product is DehydraTECH: It is a platform technology that can be used with various API's. The company is currently developing DehydraTECH-based versions of nicotine, CBD, and caffeine. It also has several other APIs in its pipeline.
- Market share: Lexaria does not currently have a significant market share in the drug delivery or consumer product markets. However, DehydraTECH has the potential to disrupt these markets by improving the effectiveness of various APIs.
Total Addressable Market (TAM):
- The global drug delivery market was valued at approximately $143.62 billion in 2021 and is expected to reach $257.6 billion by 2028, growing at a CAGR of 9.1%.
- The global consumer health market was estimated at $786.8 billion in 2021 and is projected to reach $999.5 billion by 2028, growing at a CAGR of 4.4%.
Financial Performance:
- Lexaria reported revenue of $75,988 in 2019, $154,910 in 2020, and $498,195 in 2021.
- Net income was negligible in all three years.
- The company had negative cash flow from operations of $714,311 in 2019, $755,555 in 2020, and $3,951,918 in 2021.
- Lexaria has a significant cumulative deficit of over $77 million as of 2021.
Dividends and Shareholder Returns:
- Lexaria does not currently pay dividends.
- Shareholder returns have been negative due to the company's lack of profits.
Growth Trajectory:
- Lexaria is a pre-revenue company, and therefore, its historical growth rate is not meaningful.
- Future growth will depend on the successful development and commercialization of DehydraTECH-based products.
- Recent product launches and strategic initiatives include the launch of several DehydraTECH-based products in the dietary supplement market. These include nicotine gum, cannabidiol (CBD) sublingual strips, and nicotine pouches.
Market Dynamics:
- The drug delivery market is highly competitive and fragmented. There are many existing players with established products.
- The consumer health market is also competitive, with large established players dominating the sector.
- Technological advancements in drug delivery and consumer health products are ongoing, leading to rapid innovation in the field. Lexaria must keep pace with advancements to ensure its technology remains effective.
Competitors:
- Key competitors in the drug delivery market include Catalent, Lonza, and AptarGroup.
- Key competitors in the consumer health market include Pfizer, GSK, and Bayer.
Potential Challenges and Opportunities:
- Challenges:
- Obtaining regulatory approval for DehydraTECH-based products in various markets.
- Demonstrating efficacy and safety of their products to healthcare professionals.
- Raising additional capital through debt or equity offerings to support their growth strategy.
- Competing with larger and more established players in the market.
- Opportunities:
- DehydraTECH's potential to improve the efficacy and delivery of various APIs can be attractive to pharmaceutical and consumer products companies.
- The company could form strategic partnerships to accelerate its product development and commercialization efforts.
- The rapidly growing health and wellness market presents a significant opportunity for DehydraTECH-based products.
Recent Acquisitions:
- Lexaria has not reported any acquisition activities in the past three years.
AI-Based Fundamental Rating:
A comprehensive analysis and an AI-based fundamental rating are not feasible at this time because the company is pre-revenue.
Sources and Disclaimers:
Sources for analysis and data include the company's website, press releases, SEC filings, and industry articles and reports.
Disclaimer: I am an AI chatbot and cannot provide financial advice. Data analysis and insights offered above should not be considered an endorsement for investment in Lexaria Bioscience Corp.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2006-10-10 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://lexariabioscience.com |
Full time employees 5 | Website https://lexariabioscience.com |
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.